The Biopharmaceutical Industry’s Efforts to Beat Coronavirus

Dr. Mike Ybarra, Chief of Medical Affairs

June 2020
Our Commitment to Beat Coronavirus

We are rapidly screening our vast global libraries of medicines to identify potential treatments and have numerous clinical trials underway to test new and existing therapies.

We are dedicating our top scientists and using our investments in new technologies to speed the development of safe and effective vaccines.

We are expanding our unique manufacturing capabilities and sharing available capacity to ramp up production once a successful medicine or vaccine is developed.

We are collaborating with government agencies, hospitals, doctors and others to donate supplies and medicines to help those affected around the world.

We are sharing the learnings from clinical trials in real time with governments and other companies to advance the development of additional therapies.

We are working with governments and insurers to ensure that when new treatments and vaccines are approved they will be available and affordable for patients.
Factors Contributing to the Industry’s Response

Armed with experience garnered from previous outbreaks and a vast storehouse of knowledge about infectious diseases like influenza, malaria, and HIV, researchers are working to develop and deliver diagnostics, treatments, and vaccines to save lives and restore the rhythms of daily life for billions of people.
Hundreds of these Clinical Trials are Testing 97 Unique Investigational Therapies from PhRMA Members

Data as of 6/12/2020

Source: World Health Organization International Clinical Trials Registry Platform (ICTRP)
Many of America’s Biopharmaceutical Companies Are Expanding Their Assistance Programs To Help More People

The Medicine Assistance Tool (MAT) is a web platform designed to help patients, caregivers and health care providers learn more about some of the resources available to assist in affording their medicines.

www.MAT.org
For More Resources and Information, Visit PhRMA.org/Coronavirus

- An up-to-date list of member company efforts to combat COVID-19
- A factsheet on the pipeline for new vaccine and treatments
- An open letter from PhRMA’s CEO and PhRMA’s Chairman of the Board
- The latest Catalyst blog posts on COVID-19
- An infographic on how the industry is fighting COVID-19